Microsoft word - abstract toc-titles authors only to ccfa 11-4-08

Table of Contents
O-0001. SONIC: A randomized, double-blind, controlled trial comparing Infliximab and Infliximab plus
Azathioprine to Azathioprine in patients with Crohn’s Disease naive to immunomodulators and biologic
therapy
Sandborn W1, Rutgeerts P2, Reinisch W3, Mantzaris G4, Kornbluth A5, Rachmilewitz D6, Lichtiger S5, D'Haens G7,
van der Woude C8, Diamond R9, Broussard D9, Hegedus R9, Colombel J10
1Mayo Clinic, Rochester, MN, 2University Hospital, Gasthuisburg, Leuven, Belgium, 3University Hospital Vienna,
Vienna, Austria, 4Evangelismos Hospital, Athens, Greece, 5Mount Sinai Medical Center, New York, NY, 6Shaare
Zedek Medical Center, New York, NY, 7Imelda Ziekenhuis, Bonheiden, Belgium, 8Erasmus MC Rotterdam,
Netherlands, 9Centocor, Inc., Horsham, PA, 10Centre Hospitalier Universitaire de Lille, France
O-0002. Impact of Adalimumab on Hospitalization Risk for TNF-Antagonist–Naive patients With Moderate to
Severe Crohn’s Disease
Loftus Jr E1, Feagan B2, Colombel J3, Wu E4, Yu A4, Chao J5, Mulani P5
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, US, 2Robarts Research Institute,
University of Western Ontario, London, Ontario, Canada, 3Centre Hospitalier Universitaire de Lille, Hôpital Claude
Huriez, Lille, France, 4Analysis Group, Inc., Boston, Massachusetts, US, 5Abbott Laboratories, Abbott Park, Illinois,
US
O-0003. CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn’s Disease patients with open
fistulas
Schreiber S1, Lawranc I2, Thomsen O3, Hanauer S4, Bloomfield R5, Sandborn W6
1Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany, 2University of Western Australia, Fremantle Hospital, Fremantle, Australia, 3Herlev Hospital, University of Copenhagen, Herlev, Denmark, 4University of Chicago Medical Center, Chicago, IL, US, 5UCB Pharma, Slough Berkshire, United Kingdom, 6Mayo
Clinic, Rochester, MN, US
O-0004. The TOUCH program and risk management plan for the administration of Natalizumab: Updated
safety results from the use of Natalizumab in patients with relapsing Multiple Sclerosis and Crohn’s Disease
Sands B1, Francis G2, Hogge G2, Belcher G3, Kooijmans M3, Kim R3, Lynn F3, Bozic C3
1Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, US, 2Elan Pharmaceuticals, Inc.,
South San Francisco, California, US, 3Biogen Idec, Inc., Cambridge, Massachusetts, US

O-0005. Renovating the domain structure of the Inflammatory Bowel Disease questionnaire
Awais D1, Gathany T2, Higgins P1
1University of Michigan, Ann Arbor, Michigan, US, 2Centocor, Inc., Horsham, PA, US
O-0006. Clinical significance of stool ASCA in disorders of the Ileal Pouch
Tang L1, Boone J2, Moore L1, Lopez R1, Shen B1
1Cleveland Clinic, Cleveland, OH, US, 2Tech Lab, Blacksburg, VA, US
O-0007. IBD patients need in health quality of care
Svendsen A, Laugesen B
Herlev, Denmark
O-0008. Assessing the discount rate in patients with Inflammatory Bowel Disease.
Waljee A, Waljee J, Rubenstein J, Morris A, Higgins P
University of Michigan, US
O-0009. Medication use and costs among U.S. children and adults with Inflammatory Bowel Disease
Kappelman M1, Porter C1, Finkelstein J2
1University of North Carolina, Chapel Hill, NC, US, 2Harvard Medical School, Chapel Hill, NC, US
O-0010. Comparative analysis of IBD serology
Burgunder P, Shafran I, Aplin T
Shafran Gastroenterology Center, Winter Park, FL, US

O-0011. Real world dosing of anti-tumor Necrosis factor therapies in the treatment of adults with Crohn’s
Disease
Waters H1, Meekins T2, Bewtra A2, McKenzie R1, Tang B1, Piech C1
1Centocor Ortho Biotech, Horsham, PA, US, 2Wolters Kluwer Health, Conshohocken, PA, US
O-0012. Physicians inadequately counsel Inflammatory Bowel Disease patients about Immunosuppressive
Therapy and the risk of nonmelanoma skin cancer with sun exposure
Sidhu H, Bornstein L, Chandler M, Borum M
The George Washington University Hospital, Washington DC, US
O-0013. Diagnostic ionizing radiation exposure in a population-based cohort of children with Inflammatory
Bowel Disease
Palmer L, Porter C, Kappelman M
University of North Carolina, Chapel Hill, NC, US
O-0014. Patient trust-in-physician and race are predictors of adherence to medical management in
Inflammatory Bowel Disease
Nguyen G1, LaVeist T3, Harris M2, Datta L2, Bayless T2, Brant S2
1University of Toronto, Toronto, Ontario, Canada, 2Johns Hopkins University, Baltimore, MD US, 3Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD US
O-0015. T cell signaling via the toll-receptor associated activator of interferon (TRIF) pathway protects from
the development of acute and chronic murine colitis
Breglio K1, Fukata M2, Conduah D3, Hernandez Y3, Chen A3, Goo T3, Hsu D3, Xiong H4, Xu R5, Mayer L3, Abreu M2
1Division of Pediatric Gastroenterology, Mount Sinai School of Medicine, New York, NY, US, 2Division of
Gastroenterology, University of Miami School of Medicine, Miami, FL, US, 3Division of Gastroenterology, Mount Sinai
School of Medicine, New York, NY, US, 4Department of Immunology, Mount Sinai School of Medicine, New York, NY,
US, 5Department of Pathology, New York University School of Medicine, New York, NY, US
O-0016. Dietary iron supplementation enhances dysplasia and carcinoma development in a spontaneous
ulcerative colitis model in Interleukin-2 deficiency mice
Liao J, Yang A, Zhang W, Yang G
Northwestern University, Chicago, IL, US
O-0017. Growth impairment in pediatric Inflammatory Bowel Disease: Role of parental heights and genetic
variants
Lee J1, Escher J2, Shuman M1, Kugathasan S3, Butler J1,4, Lettre G1,4, Hirschhorn J1,4, Essers J1, Sandler D1, Forbes
P1, Grand R1
1Children's Hospital Boston, Boston, MA, US, 2Sophia Children's Hospital, Rotterdam, Netherlands, 3Emory
University School of Medicine, Atlanta, GA, US, 4Broad Institute of Harvard and MIT, Cambridge, MA, US
O-0018. GM-CSF signaling maintains mucosal barrier function by promoting STAT5 dependent intestinal
epithelial cell survival and proliferation
Han X1, Gilbert S1, Ren X2, Gully J3, Jurickova I1, Samson C1, Denson L1
1Division of Gastroenterology, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH, US, 2Division
of Pulmonary Biology, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH, US, 3College of
Medicine, University of Cincinnati, Cincinnati, OH, US
O-0019. Reduced serum HMW adiponectin and colonic receptor expression contributes to immune
dysregulation in patients with Crohn’s Disease
Arsenescu R1, Bruno M2, Arsenescu V1, Rogier E2, Stefka A2, DeVilliers W1,2, Kaetzel C2
1Internal Medicine-Gastroenterology, University of Kentucky, Lexington, KY, US, 2Microbiology, Immunology &
Molecular Genetics, University of Kentucky, Lexington, KY, US
O-0020. Quantitative proteomics profiling of neoplastic progression of ulcerative colitis
Pan S1, Crispin D1, Mirzaei H2, Tamura Y1, Goodlett D1, Bronner M3, McIntosh M4, Aebersold R2, Rabinovitch P1,
Brentnall T1, Chen R1
1University of Washington, Seattle, WA, US, 2Institute for Systems Biology, Seattle, WA, US, 3Cleveland Clinic Foundation, Cleveland, OH, US, 4Fred Hutchinson Cancer Research Center, Seattle, WA, US
O-0021. Genotyping of common risk variants is informative in discerning IBD subtype
Essers J1,2, Lee J1, Grand R1, Daly M1,2,3
1Children's Hospital Boston, Boston MA, 2The Broad Institute of Harvard University and MIT, Cambridge MA, 3The
Massachusetts General Hospital, Boston MA
O-0022. An interaction between NOD2 and smoking revealed in operative recurrence of ileal Crohn’s disease
Stone C1, Chen J1, Gorbe E1, Unkart J1, McCullough C1, Hunt S1, Miller C1, Bowcock A1, Dietz D2, Li E1
1Washington University in St. Louis, MO, US, 2Cleveland Clinic, OH, US
O-0023. Impact of uncultivable bacteria on a time-dependent shift to a g colon-like h bacterial community in
pouch flora following total proctocolectomy
Kohyama A1, Ogawa H1, Funayama Y2, Takahashi K2, Benno Y3, Nagasawa K4, Tomita S4, Sasaki I1, Fukushima
K5,6
1Tohoku University, Graduate School of Medicine, Division of Biological Regulation, Sendai, Japan, 2Tohoku Rosai Hospital, Sendai, Japan, 3RIKEN BioResource Center, Microbe Division/Japan Collection of Microorganisms,Wako, Saitama, Japan, 4Tamagawa University, Department of Agricultural Chemistry, Tokyo, Japan, 5Tohoku University, Graduate School of Biomedical Engineering, Laboratory of Gastrointestinal Tract Reconstruction, Sendai, Japan, 6Tohoku University, Graduate School of Medicine, Division of Surgical and Molecular Pathophysiology, Sendai,
Japan
O-0024. Helicobacter bilis colonization enhances susceptibility to DSS-induced colitis
Henderson A1, Ramer-Tait A1, Dorn A1, Hostetter J2, Jergens A3, Wannemuehler M1
1Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, US, 2Department of
Veterinary Pathology, Iowa State University, US, 3Department of Veterinary Clinical Sciences, Iowa State University,
US
O-0025. TLR2 and TLR4 regulate B cell responses in human inflammatory bowel disease
Noronha A1, Liang Y2, Harnett W3, Harnett M3, Stucchi A4, Becker J4, Farraye F1, Ganley-Leal L2
1Boston University Medical Center, Section of Gastroenterology, Boston MA US, 2Boston University Medical Center,
Section of Infectious Disease, Boston MA US, 3Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde, Glasgow, UK, 4Boston University School of Medicine, Departments of Surgery, Pathology
and Laboratory Medicine, Boston MA US
O-0026. African and European genetic admixture in African American IBD patients
Wang M1, Kugathasan S2, Cho J3, Isaacs K4, Lewis J5, Valentine J6, Gold M7, Smoot D8, Duerr R9, Rioux J9,
Silverberg M9, Harris M1, Ford J1, Kittles R10, Brant S11 1Johns Hopkins University, Baltimore, MD, US, 2Emory
University, Atlanta, GA, US, 3Yale University, New Haven, CT, US, 4University of North Carolina, Chapel Hill, NC, US,
5University of Pennsylvania, Philadelphia, PA, US, 6University of Florida, 7Washington Hospital Center, 8Howard
University, 9University of Pittsburgh, 10University of Chicago, 11University of Montreal
O-0027. Use of the serum detection of Anti-Saccharomyces Cerevisiae Antibodies, Perinuclear Antineutrophil
Cytoplasmic Antibodies and antibodies against the exocrine pancreas and intestinal goblet cells to
differentiate between Crohn's Disease and Ulcerative
Witthoeft T1, Maass L2
1Gastroenterological Practice, Stade, Germany, 2University Hospital Schlewig Holstein Campus, Luebeck, Germany
O-0028. CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma
axis.
Hisamatsu T, Kamada N, Kobayashi T, Takayama T, Okamoto S, Hibi T
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sc, Tokyo, Japan
O-0029. The protective effect of 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) on dextran sodium sulfate-
induced colitis in mice via the induction of heme oxygenase-1
Omatsu T1, Naito Y1, Takagi T1, Hirata I1, Mizushima K1, Handa O1, Kokura S1, Ichikawa H2, Yoshikawa T1
1Dep. of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Dep. of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan
O-0030. 15-deoxy-Ģ12,14-prostaglandin J2 ameliorates dextran sodium sulfate-induced colitis in mice via
the induction of heme oxygenase-1
Hirata I, Naito Y, Takagi T, Mizushima K, Handa O, Kokura S, Ichikawa H, Yoshikawa T
Kyoto Prefectural University of Medicine, Kyoto, Japan
O-0031. The identification of ulcerative colitis-associated microRNAs and their regulation of epithelial
chemokine expression.
Kwon J1, Wu F1, Zikusoka M1, Dassopoulos T2, Brant S1, Chakravarti S1, Bayless T1
1Johns Hopkins University, Division of Gastroenterology, Baltimore, MD, US, 2Washington University School of
Medicine, Gastroenterology Division, St. Louis, MO, US
O-0032. The levels of TLR2, TLR4 and CD14 on LPS stimulated monocytes are reduced by membrane TNF
signaling of certolizumab pegol, adalimumab and infliximab
Fossati G, Nesbitt A
UCB-Celltech, Slough, United Kingdom
O-0033. Chemoprevention of ulcerative colitis-induced carcinogenesis by myo-inositol: Mainly through
inhibition of ulcerative colitis-mediated AKT/α-catenin signaling and progenitor cell activation
Yang G, Yang A, Lee G, Barret T, Zhang M, Liao J
Northwestern University, Chicago, IL, US
O-0034. Flagellin exacerbates DSS induced Colitis via TLR5 independent mechanisms
Himmel M1,2, Hardenberg G1, Ivison S2, Wark P2, Levings M1, Steiner T2
1Department of Surgery, University of British Columbia, Vancouver, Canada, 2Department of Infectious Diseases,
University of British Columbia, Vancouver, Canada
O-0035. iNOS increases colonic mucus thickness during colitis in rats
Schreiber O, Petersson J, Phillipson M, Jägare A, Holm L
Medical Cell Biology, Uppsala, Sweden
P-0001. Percutaneous injection sclerotherapy for treatment of bleeding peristomal varices
Bhushan A1, Kamath P1, McKusick M2, Sandborn W1
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, US, 2Division of Radiology, Mayo Clinic,
Rochester, MN, US
P-0002. Natural helminth therapy augments Treg cells activity and may provide a new therapeutic
opportunity in the treatment of IBD
Frapaise X
Asphelia Pharmaceuticals San Diego CA, US
P-0003. Antinuclear antibodies: A marker associated with steroid-dependence in patients with Ulcerative
Colitis
Barahona-Garrido J, Camcho-Escobedo J, García-Martínez C, Tocay H, Cabiedes J, Yamamoto-Furusho J
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
P-0004. Peripheral blood tregs (FOXP3+CD4+) in patients with Inflammatory Bowel Disease (IBD) during
treatment with anti TNFα agents
Guidi L1, Procoli A2, Mocci G1, Marzo M1, Bonanno G2, Papa A1, De Vitis I1, Fedeli G1, Rutella S3
1Internal Medicine, Università; Cattolica del Sacro Cuore, Roma, Italy, 2Gynecology,Università; Cattolica del Sacro
Cuore, Roma, Italy, 3Hematology, Università; Cattolica del Sacro Cuore, Roma, Italy
P-0005. Human Beta defensin 3 protein accumulation is increased and redirected in Crohn’s ileitis in vivo
and modulates T cell responses in vitro
Meisch J, Nishimura M, Feng Z, Ghosh S, Weinberg A, Levine A
Case Western Reserve University, Cleveland, OH, US

P-0006. Mycobacterium avium subspecies paratuberculosis reactive T-cells from intestinal biopsies of
Crohn’s disease patients.
Olsen I1,2, Tollefsen S2, Aagaard C3, Reitan L1, Sollid L2, Lundin K2,4
1National Veterinary Institute, Oslo, Norway, 2Centre for Immune Regulation, Institute of Immunology, Oslo, Norway, 3Departement of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark, 4Departement of
Medicine, Rikshospitalet, Oslo, Norway
P-0007. The effect of α4β7 blockade on T-lymphocyte trafficking to intestinal compartments in the normal
and inflamed intestine
Wang C, McDonald K, Newberry R
Washington University in Saint Louis, MO, US
P-0008. Investigation on the efficacy and immunologic mechanism of Trichinella spiralis intervening
experimental inflammatory bowel disease
Zhao Y1, Liu M1, Zou H2, Wang X1, Deng H1, Sun L1,2
1Institute of Zoonoses, Jilin University, Changchun City of Jilin Province, China, 2First Hospital, Jilin University,
Changchun City of Jilin Province, China
P-0009. Effects of the ACE2 inhibitor GL1001 on Dextran sodium sulfate-induced Colitis in mice
Byrnes J, Picarella D, Guzman L, Ellard C, Bourque L, Connelly K, Donahue S
Ore Pharmaceuticals, Inc., Cambridge, MA, US
P-0010. Development of inflammatory bowel disease models in young mice:
Yersinia enterocolitica infection as a model for pediatric Crohn’s disease
Echeverry A, Schesser K, Adkins B
University of Miami, Miami, Fl, US
P-0011. GL1001 Inhibition of ACE2 is Gastroprotective in Rat Models of Gastritits
Guzman L1, Odate S1, Boiselle C1, Gross S1, Wallace J3, Coopersmith R2, Barnes T2, Malstrom S2, Tyler S2, Ellard
C2, Bourque L2, Byrnes J2, Jacobson M4, Donahue S1
1Clinical Development Division, Ore Pharmaceuticals, Inc., Cambridge, MA, US, 2Discovery Division, Ore
Pharmaceuticals, Inc., Cambridge, MA, US, 3Department of Pharmacology and Experimental Therapeutics,
University of Calgary, Alberta, Canada, 4MDJ Consulting, LLC, Cambridge MA, US
P-0012. Inflammatory Bowel Disease causes reversible bone inflammation, osteoblast suppression, and bone
loss
Harris L1, 2, McCabe L3, 4
1Department of Cell and Molecular Biology, Michigan State University, East Lansing, Michigan, US, 2Center for
Intergrated Toxicology, Michigan State University, East Lansing, Michigan, US, 3Department of Physiology, Michigan
State University, East Lansing, Michigan, US, 4Biomedical Imaging Research Center, Michigan State University, East
Lansing, Michigan, US
P-0013. Fluoxetine inhibits nuclear factor-kappaB signaling in intestinal epithelial cells, and ameliorate acute
murine colitis and colitis-associated colon cancer
Koh S, Jung H, Song I, Kim J
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul,
Korea
P-0014. Chronic colonic inflammation in the mouse; natural infection induces Crohns-like pathology.
Pennock J1, Hankinson J2, Levison S1, McLaughlin J1, Grencis R3
1School of Medicine, University of Manchester, UK, 2CIGMR, University of Manchester, UK, 3Faculty of Life Sciences,
University of Manchester, UK
P-0015. Alterations in Mucosal Cytokine levels reflect acute inflammation but not chronic inflammation in the
Murine DSS model of Colitis
Polyak S1, Dixon L2, Wasserfall C2, Mach A1, Mah C3, Kevil C4, Valentine J1
1University of Florida, Dept. of Medicine, Gainesville, FL US, 2University of Florida, Dept. of Pathology, Immunology & Laboratory Medicine, Gainesville, FL US, 3University of Florida, Dept. of Pediatrics, Gainesville, FL US, 4Louisiana State University, Dept. of Pathology, Shreveport, LA US P-0016. Alterations in amino acid uptake and transport in TNBS-induced colitis
Puleo F, Meng Q, Navaratnarajah M, Fitzpatrick L, Koltun W, Cooney R
Penn State Milton S. Hershey Medical Center, Hershey, PA, US
P-0017. Yersinia enterocolitica infection of murine neonates: A model of pediatric inflammatory bowel
disease
Siefker D
University of Miami Miller School of Medicine, Miami, FL, US
P-0018. Rectal administration of carbon monoxide (CO)-saturated solution ameliorates trinitrobenzene
sulfonic acid-induced colitis in rats
Takagi T, Naito Y, Okuda T, Uchiyama K, Okayama T, Hirata I, Omatsu T, Suzuki T, Tsuboi H, Mizushima K, Handa
O, Kokura S, Ichikawa H, Yoshikawa T
Kyoto Prefectural University of Medicine, Kyota, Japan
P-0019. Long-Term safety of Certolizumab Pegol in Crohn’s Disease: Integrated safety findings on serious
adverse events of special interest
Colombel J1, Schreiber S2, Rutgeerts P3, Sandborn W4, Hanauer S5
1CHU Lille, Lille, France, 2Christian Albrechts University, Kiel, Germany, 3University Hospital Gasthuisberg, Leuven,
Belgium, 4Mayo Clinic, Rochester, MN, US, 5University of Chicago Medical Center, Chicago, IL, US
P-0020. Communicating information to patients with Crohn’s Disease for treatment decision making
Dudley-Brown S1, Nag A2, Fry J3, Norton B4, Hass S5, Panjabi S5
1Schools of Medicine and Nursing, Johns Hopkins University, Baltimore, Maryland, US, 2The University of Texas at
Austin, Austin, Texas, US, 3Ohio Gastroenterology and Liver Institute, Cincinnati, Ohio, US, 4Massachusetts General
Hospital, Boston, Massachusetts, US, 5Elan Pharmaceuticals, Inc., South San Francisco, California, US
P-0021. Pouchitis atlas for objective endoscopic diagnosis
Fukushima K1,2, Fujii H2, Yazmamura T2, Sugita A2, Kameoka S2, Nagawa H2, Futami K2, Watanabe T2,
Hatakeyama K2, Sawada T2, Yoshioka K2, Kusunoki M2, Konishi H2, Hibi T2.3, Sasaki I1.2
1Tohoku University, Sendai , Japan, 2Surgical research group, the research committee of inflammatory bowel
disease, the Ministry of Health, Welfare and Labor of Japan, 3Keio University
P-0022. A new non-invasive method to detect cytomegalovirus (CMV) -DNA in stool samples of patients with
inflammatory bowel disease (IBD).
Herfarth H1, Sandridge M1, Rubinas T2, Miller M2
1Division of Gastroenterology & Hepatology, University of North Carolina, Chapel Hill, NC, US, 2Department of
Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, US
P-0023. Soluble P-selectin: A potential serum biomarker for Inflammatory Bowel Disease and useful guide for
Infliximab therapy
Ku M, Rivera-Nieves J
University of Colorado Health Sciences Center, Aurora, CO, US
P-0024. Mucosal healing in ulcerative colitis: Investigating the correlation between healing of the colonic
mucosa and clinical outcomes
Lichtenstein G
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, US
P-0025. Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the
alpha4beta7 integrin
Parikh A, Fedyk E, Soler D, Wyant T, Kadambi V, Leach T, Milch C, Fox I
Millennium: The Takeda Oncology Company, Cambridge, MA, US
P-0026. Induction of remission with extended MMX™ mesalamine therapy: time to resolution of UC
symptoms
Sandborn W1, Kamm M2, Lichtenstein G3, Sumner M4, Joseph R4
1IBD Clinic, Mayo Clinic, Rochester, Minnesota, US, 2St Vincent's Hospital, Melbourne, Australia, 3Div. of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, US, 4Shire Pharmaceuticals Inc., Wayne, Pennsylvania, US
P-0027. Clinical usefulness of narrow-band imaging for the endoscopic diagnosis of Inflammatory Bowel
Disease
Takeuchi H, Yokoyama K, Haruki S, Sada M, Kobayashi K, Saigenji K
Kitasato University East Hospital, Sagamihara, Japan
P-0028. Consistency of coating thickness of delayed-release mesalamine formulations: drug release
characteristics across the pH range found in the GI tract of patients with ulcerative colitis
Tenjarla S, Romasanta V, Abinusawa A
Shire Pharmaceuticals Inc., Wayne, Pennsylvania, US
P-0029. Combining pharmacokinetic, scintigraphic and tablet dissolution analyses to investigate the drug
release profiles of delayed-release mesalamine formulations
Tenjarla S, Karlstadt R, Joseph R
Shire Pharmaceuticals Inc., Wayne, Pennsylvania, US
P-0030. Combined pharmacokinetic and scintigraphic analyses for the comparison of 5-ASA release profiles
from MMX™ mesalamine and another delayed-release mesalamine formulation
Wray H1, Joseph R2, Palmen M2, Pierce D2
1Pharmaceutical Profiles Ltd, Nottingham, United Kingdom, 2Shire Pharmaceuticals Inc., Basingstoke, United
Kingdom
P-0031. Clinical usefulness and limitations of Cytapheresis in patients with active Ulcerative Colitis
Yokoyama K, Kobayashi K, Takeuchi H, Haruki S, Sada M, Saigenji K
Kitasato University East Hospital, Sagamihara, Japan
P-0032. Squamous Cell Carcinoma in a Crohn's patient with Refractory Pyoderma Gangrenosum: A case
report
Bornstein L, Borum M
George Washington University Hospital, Washington D.C., US
P-0033. Small bowel malignancy in Crohn’s Disease: An opportunity for surveillance?
Davison A, Bayless T
Johns Hopkins Hospital, Department of Gastroenterology, Columbia, MD, US
P-0034. Large duodenal enteric fistula caused voluminous vomiting in a patient with Crohn’s disease
Fan X, Scott L, Sellin J
University of Texas Medical Branch, Galveston, TX, US
P-0035. First case report of Adalimumab induced psoriasis in Crohn's Disease
Harris M, Richards R
Stony Brook University Medical Center, Stony Brook, NY, US
P-0036. Life threatening complications of sulphasalazine therapy in pediatric inflammatory bowel disease
Hussey S1,2, Ooi K1,2, Zachos M1,2
1The Hospital for Sick Children, Toronto, Ontario, Canada, 2University of Toronto, Toronto, Ontario, Canada
P-0037. Systemic amyloidosis masquerading as refractory ulcerative colitis
Koslowe O1, Hoffman J2, Comenzo R2
1New York Presbyterian- Weill Cornell, New York, NY, US, 2Memorial Sloan-Kettering Cancer Center, New York, NY,
US
P-0038. Pulmonary nodules in 3 adolescents with Crohn’s Disease
Mallah H, Brown M, Rossi T
University of Rochester, Rochester, NY, US
P-0039. Severe hepatic steatosis after use of infliximab in Crohn´s Disease
Santana G, Rodrigues M, Espinheira L, Bêda C, Castro Lyra A
Federal University of Bahia, Salvador, Brazil
P-0040. Natalizumab (Tysabri®) in complicated Crohn's disease: A single center experience.
Sheikh S, Plevy S
University of North Carolina, Chapel Hill, NC

P-0041. Leukocytopenia After Azathioprine With 5-Aminosalicylates Treatment In Ulcerative Colitis: Report
Of Two Cases.
Shinkai H, Shiraki M, Okuzono T, Yaguchi K, Asonuma S, Kayaba S
Department of Internal Medicine, Isawa Prefectural Hospital, Oushu, Japan
P-0042. Laparoscopic surgery for Ileocaecal Crohns Disease: A single centre experience from the UK
Khan J, Kaushal M, Hendricks J, Arulampalam T, Austin R, Motson R
Colchester, Essex, UK
P-0043. Infliximab-induced psoriasis in pediatric Crohn Disease; Experience of this paradoxical event at a
tertiary centre
Sherlock M, Frost K, Zachos M, Griffiths A
The Hospital for Sick Children, Toronto, Canada
P-0044. Minimally invasive total Proctocolectomy with Brooke Ileostomy for Ulcerative Colitis
Holubar S, Privitera A, Cima R, Dozois E, Pemberton J, Larson D
Mayo Clinic, Rochester, MN, US
P-0045. Laparoscopic surgery for recurrent Ileocolic Crohn’s Disease
Holubar S, Privitera A, Cima R, Dozois E, Pemberton J, Larson D
Mayo Clinic, Rochester, MN, US
P-0046. A randomized trial of a probiotic preparation VSL#3 for inducing and maintaining clinical response in
patients with active microscopic colitis
Ahuja V1, Makharia G1, Rohatgi S1, DeSimone C2, Sahu A3
1Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India, 2University of L'Aquila,Rome, Italy, 3Cd Pharma India (a VSL affiliate), New Delhi, India
P-0047. Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label
Phase of PROTECT-1 in Crohn's Disease
Bekker P1, Johnson D1, Hamilton G1, Keshav S2, Schall T1
1ChemoCentryx, Inc., Mountain View, CA, US, 2Gastroenterology, John Radcliffe Hospital, Oxford, UK
P-0048. EGCG, a Green Tea Catechin, reduces pro-inflammatory cytokine production by CD14+
Macrophages, Lymphocytic CD45+RO T cells, and mixed macrophage/T cell populations from IBD patients
and controls.
Qazzaz H1, Fernandez R1, Linder M1, Bon-Homme M1, Tucker W1, Dryden G2
1Pathology and Laboratory Medicine University of Louisville, KY, US, 2Division of Gastroenterology University of
Louisville, KY, US
P-0049. Safety of Adalimumab in patients with Crohn’s Disease: Analysis of global clinical trials
Colombel J1, Pannaccione R2, Sandborn W3, Rutgeerts P4, Hanauer S5, Reinisch W6, Pollack P7, Kent J8, Cardoso
A8, Lau W7
1Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France, 2Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 3Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, US, 4University Hospital of Gasthuisberg, Leuven, Belgium, 5University of Chicago, Chicago, Illinois, US, 6Medical University of Vienna, Vienna, Austria, 7Abbott Laboratories, Parsippany, New Jersey, US, 8Abbott
Laboratories, Abbott Park, Illinois, US
P-0050. Endoscopic Mucosal improvement in patients with active Crohn's Disease treated with Certolizumab
Pegol: First results of the MUSIC Clinical Trial
Colombel J1, Lemann M2, Bouhnik Y3, Dewit O4, Dupas J5, Ross M6, D’Haens G7, Mitchev K8, Vermeire S9, Brixi-
Benmansour H10, Moreels T11, Hébuterne X12
1CHU Lille, Lille, France, 2Hôpital Saint-Louis, Paris, France, 3Hôpital Beaujon, Clichy, France, 4UCL Saint Luc, Brussels, Belgium, 5CHU Amiens, Amiens, France, 6Special Medical Practice, Berlin, Germany, 7Imelda General Hospital, Bonheiden, Belgium, 8UCB, Braine l'Alleud, Belgium, 9University Hospital Gasthuisberg, Leuven, Belgium, 10CHU Reims, Reims, France; 11Antwerp University Hospital, Antwerp, Belgium; 12CHU Nice, Nice, France P-0051. Quality of life improvements with Natalizumab maintenance therapy in patients exposed to or failing
TNF-alpha inhibitor therapy in the ENACT-2 Trial
Feagan B1, Panaccione R2, Hass S3, Panjabi S3
1Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 2Inflammatory Bowel Disease
Clinic, University of Calgary, Calgary, Alberta, Canada, 3Elan Pharmaceuticals, Inc., South San Francisco, California,
US
P-0052. Efficacy of delayed-release Mesalamine 4.8g/d (800mg tablet) for treatment of moderate UC in
patients with a history of difficult to treat disease: Analysis of 3 double-blind, active-controlled trials
Hanauer S1, Ramsey D2, Sandborn W3
1University of Chicago Medical Center, Chicago, IL, US, 2Procter & Gamble Pharmaceuticals, Inc., Mason, OH, US, 3Mayo Clinic, Rochester, MN, US
P-0053. Improvement of quality of life in patients with moderate ulcerative Colitis treated with delayed-
release oral Mesalamine 4.8g/day (800 mg tablet)
Irvine E1, Ramsey D2, Higgins P3
1St. Michael's Hospital, University of Toronto, Toronto, ON, Canada, 2Procter & Gamble Pharmaceuticals, Inc.,
Mason, OH, US, 3University of Michigan Medical Center, Ann Arbor, MI, US
P-0054. Impact of a pediatric IBD action plan on disease knowledge, patient experience and self-efficacy
Knupp J, Kim S, Sharpless V, Galanko J, Martin C, Kappelman M
University of North Carolina at Chapel Hill, NC, US
P-0055. Randomized trial of once-daily or three-times-daily granulated Mesalamine equally effective for
treatment of Ulcerative Colitis
Kruis W
Evangelisches Krankenhaus Kalk, Germany
P-0056. Early and sustained efficacy of delayed-release oral Mesalamine in moderately active ulcerative
Colitis patients: Combined results from the ASCEND I, II, & III trials
Lichtenstein G1, Ramsey D2, Loftus E3
1Hospital of the University of Pennsylvania, Philadelphia, PA, US, 2Procter & Gamble Pharmaceuticals, Inc., Mason,
OH, US, 3Mayo Clinic, Rochester, MN, US
P-0057. Response to Adalimumab Therapy in bio-naive patients and in Infliximab nonresponders: Results of
a Phase IIIb Clinical Trial
Lofberg R1, Louis E2, Reinisch W3, Kron M4, Camez A4, Pollack P5
1IBD-Unit, Karolinska Institutet, Stockholm, Sweden, 2University of Liège, Liège, Belgium, 3Medical University of
Vienna, Vienna, Austria, 4Abbott GmbH & Co. KG, Ludwigshafen, Germany, 5Abbott Laboratories, Parsippany, New
Jersey, US
P-0058. The INSPIRE study: Does stress management intervention improve course of IBD and disease
specific quality of life in distressed patients with Ulcerative colitis and Crohn’s disease?
Lundin K3,4, Jahnsen J10, Leganger S2, Mokleby K2, Tangen T5,6, Jantschek I7, Wojniusz S2, Rivelsrud A6, Hausken
T8, Benningshoven D7, Jantschek G7, Rodseth A10, Wilhelmsen I9, Malt U1,2, Boye B1,2
1Institute of Psychiatry, University of Oslo, Norway, 2Department of Neuropsychiatry and Psychosomatic Medicine, Division of Clinical Neurosciences, Rikshospitalet University Hospital, Oslo, Norway, 3Department of Internal Medicine, Gastroenterology section, Division of Medicine, Rikshospitalet University Hospital, Oslo, Norway, 4Rikshospitalet Faculty Group, University of Oslo, Norway, 5Institute of Clinical Medicine, Section of Psychiatry, Haukeland University Hospital, University of Bergen, Norway, 6Department of Psychiatry, Haukeland University Hospital, Bergen, Norway, 7Department of Psychosomatic and Psychotherapy, University-clinic Schleswig-Holstein, Campus Lübeck, Germany, 8Department of surgery, Haukeland University Hospital, Bergen, Norway, 9Institute of Internal Medicine, University of Bergen, Norway; and Haraldsplass Deaconal Hospital, Bergen, Norway, 109Department of Gastroenterology, Aker University Hospital, Oslo, Norway
P-0059. Impact of Adalimumab therapy after 12 Weeks in patients with Crohn’s Disease who were
nonresponders at week 4
Panaccione R1, Sandborn W2, Colombel J3, Pollack P4, Chen N4, Chao J5, Mulani P5
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, US, 3Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France, 4Abbott Laboratories, Parsippany, New Jersey, US, 5Abbott Laboratories, Abbott Park, Illinois, US P-0060. Quality of life improvements with Natalizumab induction therapy in patients exposed to or failing
TNF-alpha inhibitor therapy in the ENCORE Trial
Panaccione R1, Feagan B2, Hass S3, Panjabi S3
1Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada, 2Robarts Research Institute,
University of Western Ontario, London, Ontario, Canada, 3Elan Pharmaceuticals, Inc., South San Francisco,
California, US
P-0061. The long-term, 30-month, efficacy and tolerability of Certolizumab Pegol Therapy for Crohn’s Disease
Sandborn W1, Lichtenstein G2, Schreiber S3, Feagan B4
1Mayo Clinic, Rochester, MN, US, 2University of Pennsylvania School of Medicine, Philadelphia, PA, US, 3Christian-
Albrechts University, Kiel, Germany, 4Robarts Research Institute, University of Western Ontario, London, Canada
P-0062. Safety of delayed-release oral Mesalamine 4.8 g/day (800 mg tablet) for treatment of active UC:
Combined analysis from 3 Randomized, double-blind, active-controlled trials
Sandborn W1, Hosterman M2
1Mayo Clinic, Rochester, MN, US, 2Procter & Gamble Pharmaceuticals, Inc., Mason, OH, US
P-0063. Benefits of Adalimumab dosage adjustment for patients with Crohn’s Disease: An analysis of the
CHARM study
Sandborn W1, Colombel J2, Rutgeerts P3, Pollack P4, Chao J5, Mulani P5
1Mayo Clinic, Rochester, Minnesota, US, 2Centre Hospitalier Universitaire de Lille, Lille, France, 3University Hospital
of Gasthuisberg, Leuven, Belgium, 4Abbott Laboratories, Parsippany, New Jersey, US, 5Abbott Laboratories, Abbott
Park, Illinois, US
P-0064. 5-Aminosalicylic Acid and its major metabolite levels in patients with moderately active ulcerative
Colitis following oral administration of delayed-release Mesalamine tablets
Sandborn W1, Balan G2, Ajayi F2
1Mayo Clinic, Rochester, MN, US, 2Procter & Gamble Pharmaceuticals, Inc., Mason, OH, US
P-0065. Monitoring treatment-specific adherence and outcomes in patients with Ulcerative Colitis
Shafran I, Burgunder P
Shafran Gastroenterology Center, Germany
P-0066. Efficacy and Safety of Certolizumab Pegol in patients with active Crohn’s Disease who previously
lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study
Vermeire S1, Abreu M2, D’Haens G3, Colombel J4, Mitchev K5, Fedorak R6, Spehlmann M7, Lee S8, Sandborn W9,
Rutgeerts P1
1University Hospital Gasthuisberg, Leuven, Belgium, 2University of Miami, Miami, FL, US, 3Imelda General Hospital, Bonheiden, Belgium, 4CHU Lille, Lille, France, 5UCB, Braine l’Alleud, Belgium, 6University of Alberta, Edmonton, AB, Canada, 7University of California, La Jolla, CA, US, 8University of Washington School of Medicine, Seattle, WA, US, 9Mayo Clinic, Rochester, MN, US
P-0067. Platelet activating factor-induced inflammatory responses in human intestinal epithelial cells are
CARMA3/Bcl10/MALT1-dependent
Dudeja P1,2
1Univ. of Illinois at Chicago, IL, US, 2Jesse Brown VA Medical Center, Chicago, IL, US
P-0068. Upregulation of a novel autocrine synthetic pathway for 1,25-dihydroxy-vitamin D3 in intestinal
epithelial cells
Graupner G, Walter M, Baylink D
Dept. of Medicine, Loma Linda University School of Medicine, Loma Linda, CA, US
P-0069. Reduced expression of G-CSF in intestinal mononuclear cells from non-inflamed regions is
associated with inflammatory bowel disease
Martins A1, Colqhoun P3, Reid G1,4, Kim S1,2,4
1Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, 2Infectious Diseases Research Group, Siebens-Drake Research Institute, University of Western Ontario, London, Ontario, Canada, 3Department of Surgery, London Health Sciences, London, Ontario, Canada, 4Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, London, Ontario, Canada P-0070. Patterns of de novo Inflammatory cytokines production in the small intestine in rat models of
experimental colitis
Mourad F1, Barada k1, Hamdi T2, Nassar C2, Saadé N2
1Departments of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon., 2Human
Morphology and Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
P-0071. Identifying children diagnosed with inflammatory bowel disease using health administrative data
Benchimol E1, Guttmann A2, Griffiths A1, Rabeneck L3, To T4
1Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, Canada, 3Division of Gastroenterology, Sunnybrook Health
Sciences Centre, Toronto, Canada, 4Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
Canada
P-0072. Impact of long-term Adalimumab treatment on fistula healing in patients with moderate to severe
Crohn’s Disease
Colombel J1, Kamm M2, Schwartz D3, Panaccione R4, Li J5, Lomax K6, Pollack P6
1Centre Hospitalier Universitaire de Lille, Lille, France, 2St Vincent’s Hospital & Melbourne University, Melbourne,
Australia, and Imperial College, London, United Kingdom, 3Department of Gastroenterology, Vanderbilt University,
Nashville, Tennessee, US, 4Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 5Abbott
Laboratories, Abbott Park, Illinois, US, 6Abbott Laboratories, Parsippany, New Jersey, US
P-0073. Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in
managing Crohn’s Disease
Feagan B1, Tan S2, Malone D3, Hinojosa J4, Brown M2
1Robarts Research Institute, London, Canada, 2UCB, Slough, UK, 3University of Arizona, Tucson, AZ, US, 4Hospital
Sagunto, Valencia, Spain
P-0074. Adalimumab maintenance therapy for patients with Crohn’s Disease is cost effective compared with
nonbiologic maintenance therapy
Feagan B1, Loftus, Jr E2, Johnson S3, Wu E3, Yu A3, Chao J4, Mulani P4
1University of Western Ontario, London, Ontario, Canada, 2Mayo Clinic College of Medicine, Rochester, Minnesota,
US, 3Analysis Group, Inc., Boston, Massachusetts, US, 4Abbott Laboratories, Abbott Park, Illinois, US
P-0075. Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohn’s
Disease: Results From open-label extension of the CHARM trial
Hanauer S1, Kamm M2, Panaccione R3, Colombel J4, Sandborn W5, Pollack P6, McIlraith M7
1University of Chicago, Chicago, Illinois, US, 2St Vincent’s Hospital & Melbourne University, Melbourne, Australia, and
Imperial College, London, United Kingdom, 3Department of Medicine, University of Calgary, Calgary, Alberta,
Canada, 4Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France, 5Division of Gastroenterology
and Hepatology, Mayo Clinic, Rochester, Minnesota, US, 6Abbott Laboratories, Abbott Park, Illinois, US, 7Abbott
GmbH & Co. KG, Ludwigshafen, Germany
P-0076. African American patients with Inflammatory Bowel Disease may have more osteoporosis when
screened with Dexa compared to white patients
Hatara M, Michener K, Khanijow V, Borum M
Division of Gastroenterology and Liver Diseases, George Washington University Washington, DC, US
P-0077. Rapid Infliximab Infusions in pediatric IBD
Hoffenberg E1, Yeckes A2
1University of Colorado Denver Health Sciences Center and The Children’s Hospital, Aurora, CO, US, 2The Children's
Hospital, CO, US
P-0078. Distribution and manifestations of Inflammatory Bowel Disease in non Caucasians: A systematic
review
Hou J, El-Serag H, Thirumurthi S
Baylor College of Medicine, Houston, TX, US
P-0079. Physicians inadequately document Corticosteroid side effect counseling in Inflammatory Bowel
Disease patients
Kashyap A, Nguyen H, Bakshi A, Borum M
Division of Gastroenterology and Liver Diseases, George Washington University, Washington, DC, US
P-0080. Fistula healing during Adalimumab treatment of patients with Crohn’s Disease who lost response to
or did not respond to Infliximab
Lichtiger S1, Binion D2, Wolf D3, Present D2, Lomax K4, Rafiq S4, Holdbrook F4
1Mount Sinai Medical Center, New York, NY, US, 2Medical College of Wisconsin, Milwaukee, Wisconsin, US, 3Atlanta
Gastroenterology Associates, Atlanta, Georgia, US, 4Abbott Laboratories, Parsippany, New Jersey, US
P-0081. Causes of death in patients with Ileal pouch-anal Anastomosis- Experience in subspecialty Pouchitis
Clinic
Moore L1,2, Shen B1,2
1Cleveland Clinic Digestive Disease Institute, Cleveland, OH, US, 2Cleveland Clinic Lerner College of Medicine,
Cleveland, OH, US
P-0082. The prevalence of metabolic syndrome in Japanese patients with Inflammatory Bowel Disease
Nagahori M1, Kubota D2, Akiyama J1, Hyun S1, Totsuka T1, Watanabe M1
1Tokyo Medical and Dental University, Tokyo, Japan, 2Aizawa Hospital, Mastumoto, Nagano, Japan
P-0083. Males with Inflammatory Bowel Disease are infrequently screened for osteoporosis
Nguyen H, Bakshi A, Borum M
Division of Gastroenterology and Liver Diseases, George Washington University, Washington, DC, US
P-0084. Budesonide for maintenance of remission in Crohn's disease: A systematic review and meta-analysis
for the Cochrane Collaboration.
Benchimol E1, Seow C2, Otley A3, Steinhart A2
1The Hospital for Sick Children, Toronto, Ontario, Canada, 2Mount Sinai Hospital, Toronto, Ontario, Canada, 3IWK
Health Centre, Halifax, Nova Scotia
P-0085. Adalimumab maintains long-term remission through 2 years in patients with moderate to severe
Crohn’s Disease
Panaccione R1, Colombel J2, Sandborn W3, Rutgeerts P4, D'Haens G5, Lomax K6, Li J7, Pollack P6
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 2Centre Hospitalier Universitaire de Lille,
Hôpital Claude Huriez, Lille, France, 3Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester,
Minnesota, US, 4University Hospital of Gasthuisberg, Leuven, Belgium, 5Imelda GI Clinical Research Center,
Bonheiden, Belgium, 6Abbott Laboratories, Parsippany, New Jersey, US, 7Abbott Laboratories, Abbott Park, Illinois,
US
P-0086. Prevalence of Inflammatory Bowel Disease in an insured population in Puerto Rico during 2005
Vendrell R1, Perez C1, Torres E1, Morell C2, Roman R2, Venegas H1
1University of Puerto Rico, San Juan, Puerto Rico, US, 2Research and Biostatistics Unit, Triple S Inc, San Juan,
Puerto Rico, US
P-0087. Inflammatory Bowel Disease patients’ adherence to and satisfaction with treatment
Waters H1, Annunziata K2, Naim A1, Freedman D2, Piech C1
1Centocor Ortho Biotech, Horsham, PA, US, 2Consumer Health Sciences International, US
P-0088. Patient perception of disease control in Ulcerative Colitis
Waters H1, Berg S2, Kelly J1, Piech C1
1Centocor Ortho Biotech Services, Horsham, PA, US, 2GfK V2, LLC., Blue Bell, PA, US
P-0089. A cost-efficacy analysis model for physician administered anti-tumor Necrosis factor agents in
Crohn’s Disease
Waters H, McKenzie R, Tang B, Piech C
Centocor Ortho Biotech Services, Horsham, PA, US
P-0090. Cost-effectiveness of Natalizumab in patients with Crohn’s Disease who have failed TNF-alpha
inhibitor therapy
Wolf D1, Sands B2, Panjabi S3, Niecko T4, Hass S3, Lacey L5
1Atlanta Gastroenterology Associates, Atlanta, Georgia, US, 2Massachusetts General Hospital, Boston, Massachusetts, US, 3Elan Pharmaceuticals, Inc., South San Francisco, California, US, 4Niecko Health Economics, LLC, Escondido, California, US, 5Elan Pharmaceuticals Ltd, Dublin, Ireland P-0091. Analysis of card15/NOD2 G908R, DLG5 R30Q and OCTN1 F503L polymorphisms and intestinal and
extra-intestinal symptoms of the disease among patients with Crohn Disease in Polish population
Jakubowska L1,3, Kaczmarek M2, Hoppe-Go³êbiewska J2, S³omski R2, Linke K1, Dobrowolska-Zachwieja A1
1Dept. of Gastroenterology, Human Nutrition and Internal Diseases, Poznañ, Poland, 2Institute for Human Genetics
Polish Academy of Sciences, Strzeszyñska Street 32, Poznañ , Poland, 3Studium for Molecular Medicine, Warsaw,
Poland
P-0092. Identification and characterization of a new Isoform of NKX2-3 mRNA from human intestine of IBD
patients
Lin Z1, Lin Y1, Hegarty J1, Wang Y2, Peterson B2, Kelly A1, Poritz L1, Koltun W1
1Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, PA. US, 2Department of
Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA, US
P-0093. Concurrence of Crohn’s and Familial Mediterranean fever diseases for Armenian cohort
Touitou I1, Pepoyan A2
1Unité médicale des maladies auto-inflammatoires, Montpellier, France, 2Armenian State Agrarian University,
Yerevan, Armenia
P-0094. Expression of gene NKX2-3 is upregulated in B cell lines and intestine of IBD patients
Yu W1, Lin Z1, Xu N2, Poritz L1, Wang Y1, Koltun W1
1Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, PA, US, 2Cancer institute,
University of Pennsylvania, Philadelphia, PA. US
P-0095. Effects of murine strain variation on intestinal antimicrobial peptide expression
Gulati A, Patel K, Sartor R
University of North Carolina, Chapel Hill, NC, US
P-0096. Macrophage polarization is determined by the underlying immunologic environment in the DNBS
colitis model
Schaefer K, Harris G, Murray B, Smith S, Saubermann L
University of Rochester Medical Center, Rochester, NY, US
P-0097. Dendritic cell-mediated suppression of DSS colitis
Tuna H1, Qualls J2, Avdiushko R1, Kaplan A1, Cohen D1
1University of Kentucky, Lexington, KY, US, 2St. Jude Children's Research Hospital, Memphis, TN, US
P-0098. TNBS induced colitis is ameliorated in rats with a great diversity in the colonic micro flora.
Petersson J1, Phillipson M1, Henriksnäs J1, Jacobsson H2, Schreiber O1, Engstrand L2, Perry M3, Holm L1
1Uppsala University, Uppsala, Sweden, 2Swedish Institute for Infectious Disease Control, Sweden, 3New South
Wales University, UK
P-0099. Osteopontin mediates Citrobacter rodentium-induced colonic epithelial cell hyperplasia
Wine E1, 2, Shen-Tu G1, 2, Ngan B1, Sodek J2, Zohar R2, Sherman P1, 2
1Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada, 2University of Toronto, Toronto, Ontario,
Canada
P-0100. Vitamin D screening by gastroenterologists is affected by steroid use in Inflammatory Bowel Disease
patients
Bakshi A, Ngugen H, Borum M
The George Washington University Hospital, Washington, DC, US
P-0101. Osteoporosis screening in Inflammatory Bowel Disease patients: The impact of an educational
initiative
Bakshi A, Nguyen H, Tishon J, Borum M
The George Washington University Hospital, Washington DC, US
P-0102. Atypical perinuclear anti-neutrophil cytoplasmic antibodies (X-ANCA) are associated with disease
extent and arthralgia in patients with Ulcerative Colitis
Barahona-Garrido J1, 2, Cabiedes J1, Yamamoto-Furusho J1, 2
1Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 2Universidad Nacional Autónoma de México P-0103. Screening for tuberculosis in Inflammatory Bowel Disease patients treated with immunosupressant
medications versus Anti-TNF medications
Bornstein L, Sidhu H, Borum M
George Washington University Hospital, Washington, DC, US
P-0104. Correlation and variability in fecal calprotectin measurement
Johnson L, McHenry A, Awais D, Higgins P
University of Michigan, Ann Arbor, MI, US
P-0105. Role of 3-dimensional endoanal ultrasound in the assesstment of perianal disfunction
Maisto F1, Romano S2, Reginelli A1, Casale L1, Liquori P1, Lombardi G1, Grassi R1
1Institute of Radiology Second University of Naples, Italy, 2AORN Cardarelli Naples, Italy

P-0106. Fecal methylated markers for the detection of adenocarcinoma in Ileal pouches of patients with
underlying ulcerative colitis
Obusez E1, Shen L3, Bennett A2, Guo B3
1Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, US, 2Digestive Diseases Institute,
Cleveland Clinic, Ohio, US, 3Department of Chemistry, Cleveland State University, Cleveland, Ohio, US
P-0107. Dedicated MDCT examination in the inflammatory disease of the small bowel: a comparison of two
methodologies (enteroclysis and enterography). Indication, results and limits.
Romano S1, Maisto F2, Russo A2, Romano L1
1A.Cardarelli Hospital - Department of Diagnostic Imaging, Naples, Italy, 2Institute of Radiology - Second University of
Naples, Italy
P-0108. 64- and 16-detector rows CT in differential diagnosis of acute abdomen from inflammatory conditions
of the intestine in emergency
Romano S1, Maisto F2, Russo A2, Romano L1
1A.Cardarelli Hospital - Department of Diagnostic Imaging, Naples, Italy, 2Institute of Radiology, Second University of
Naples, Italy
P-0109. The role of methionine metabolism in Inflammatory Bowel Disease
Benight N, Burrin D, Stoll B, Puiman P
Baylor College of Medicine, Houston, TX, US
P-0110. Inflammatory Bowel Disease and Trichuris muris
Bhardwaj E1, Else K2, Warhurst G3, Rogan M1
1University of Salford, Manchester, UK, 2University of Manchester, Manchester, UK, 3Hope Hospital, Salford,
Manchester, UK
P-0111. Rising incidence of Inflammatory Bowel Disease among children: A 12-year study
Malaty H
Baylor College of Medicine, Houston, TX, US
P-0112. Microarray analysis in TNBS colitis: invivo effect of combination therapy with N-acetylcysteine and
mesalamine on colonic tissue gene expression.
Malhotra S1, Ancha H3, Briggs J1, Knowlton N2, Frank B2, Centola M2, Payne A1, Harty R1,3
1Altheus Therapeutics, Inc., Oklahoma City, OK, US, 2Oklahoma Medical Research Foundation, Oklahoma City, OK,
US, 3University of Oklahoma HSC, Oklahoma City, OK, US

P-0113. The profile of depression in adolescents with Inflammatory Bowel Disease: Implications for
treatment
Szigethy E1, Craig A1, Lobst E1, Grand R2, Keljo D1, DeMaso D2, Noll R11Children's Hospital, Pittsburgh, PA, USA,

Source: http://www.advancesinibd.org/archive/2008/Abstract%20TOC-Titles%20Authors%20Only%20to%20CCFA%2011-4-08.pdf